What are the recommended treatment options for chronic hepatitis B, including dosing and selection criteria?

Hepatitis B Treatment

For chronic hepatitis B, initiate treatment with entecavir or tenofovir as first-line oral antiviral therapy in patients with HBV DNA ≥2,000 IU/mL and either elevated ALT, evidence of significant liver disease, or cirrhosis. These high-barrier nucleos(t)ide analogues (NAs) provide superior viral suppression with minimal resistance risk compared to older agents 1, 2.

Treatment Selection by Clinical Scenario

HBeAg-Positive Chronic Hepatitis

• First-line therapy: Entecavir 0.5 mg daily or tenofovir (TDF 245 mg or TAF) as monotherapy 1
• Alternative: Peginterferon-α for 48 weeks in non-cirrhotic patients who prefer finite therapy, though response rates are lower (32% HBeAg seroconversion) 3, 4
• Treatment endpoint: Continue NAs until at least 12 months after HBeAg seroconversion with undetectable HBV DNA 3
• Optimal candidates for peginterferon: Younger patients with elevated ALT (>2x ULN), lower HBV DNA levels, and no cirrhosis who desire a defined treatment course 4, 5

HBeAg-Negative Chronic Hepatitis

• First-line therapy: Entecavir or tenofovir monotherapy 1
• Duration: Long-term treatment required, ideally until HBsAg loss 3, 4
• Peginterferon option: 48 weeks for those preferring finite therapy, though sustained off-treatment response is uncommon 3, 4
• Treatment threshold: HBV DNA >2,000 IU/mL with elevated ALT or evidence of at least moderate fibrosis 4, 5

Compensated Cirrhosis

• Mandatory treatment if: HBV DNA ≥2,000 IU/mL regardless of ALT levels 1
• Consider treatment even if: HBV DNA <2,000 IU/mL to prevent decompensation 1
• Agent selection: Entecavir or tenofovir monotherapy only—avoid low-barrier agents due to resistance risk 1, 3, 1
• Peginterferon: May be used cautiously in well-compensated patients with preserved liver function, but requires close monitoring 1
• Duration: Long-term therapy required; discontinuation only after HBsAg loss in HBeAg-negative patients or 12 months post-HBeAg seroconversion in HBeAg-positive patients 3

Decompensated Cirrhosis

• Urgent treatment: Initiate immediately if HBV DNA detectable by PCR, regardless of ALT 1
• Agent selection: Entecavir or tenofovir monotherapy 1
• Contraindication: Peginterferon-α is absolutely contraindicated due to risk of hepatic failure 1
• Concurrent planning: Evaluate for liver transplantation simultaneously, as clinical improvement requires 3-6 months and hepatic failure may progress despite therapy 1
• Duration: Lifelong treatment required 1

Why Not Lamivudine or Adefovir First-Line?

While older guidelines from 2004-2008 recommended lamivudine and adefovir 6, 5, 6, these agents are no longer preferred for initial therapy due to:

• Lamivudine: High resistance rates (69% at 5 years) despite good tolerability 5, 7
• Adefovir: Inferior antiviral potency compared to tenofovir and nephrotoxicity risk 5, 6
• Current role: Reserved only for special circumstances (pregnancy, short-term chemoprophylaxis, HIV coinfection as part of combination regimen) 5

Treatment Thresholds and Monitoring

Initiation Criteria

• HBV DNA >20,000 IU/mL + ALT >2x ULN: Treat regardless of histology 4, 8
• HBV DNA >2,000 IU/mL + liver stiffness >9-12 kPa: Treat regardless of ALT 8
• HBV DNA >2,000 IU/mL + at least moderate histological lesions: Treat regardless of ALT 4, 8
• Any detectable HBV DNA in cirrhosis: Treat regardless of ALT 4, 5, 8

Response Definitions

• Complete virological response: Undetectable HBV DNA by real-time PCR 3
• Primary non-response to NAs: <2 log₁₀ IU/mL decrease after 6 months 3
• Virological breakthrough: >1 log₁₀ IU/mL increase from nadir 3, 4

Monitoring Schedule

• Chronic hepatitis with normal ALT: Test liver function and HBV DNA every 2-6 months 1
• Chronic hepatitis with elevated ALT: Test liver function every 1-3 months, HBV DNA every 2-6 months 1
• Compensated cirrhosis: Test liver function and HBV DNA every 2-6 months 1
• Decompensated cirrhosis: Test liver function every 1-3 months, HBV DNA every 2-6 months 1

Critical Pitfalls to Avoid

Do not use peginterferon in decompensated cirrhosis—this can precipitate hepatic failure and is absolutely contraindicated 1.

Do not start lamivudine or telbivudine for long-term therapy in cirrhotic patients—the high resistance rates (up to 69% at 5 years) can lead to virological breakthrough, hepatitis flares, and potentially fatal decompensation 3, 5, 7.

Do not stop NAs prematurely in HBeAg-negative patients—treatment should continue until HBsAg loss, as early discontinuation leads to high relapse rates 3, 4.

Monitor for virological breakthrough every 3-6 months—early detection allows intervention before biochemical breakthrough and clinical deterioration 3, 4.

Special Populations

Pregnancy

• Switch to tenofovir or telbivudine (pregnancy category B) if already on treatment 5
• Consider third-trimester prophylaxis in women with high viremia to prevent vertical transmission 8

Immunosuppression/Chemotherapy

• Initiate prophylactic lamivudine at chemotherapy onset, continue 6 months post-completion 6
• Screen all high-risk patients for HBsAg before immunosuppressive therapy 6

HIV Coinfection

• Use lamivudine 150 mg twice daily or tenofovir as part of antiretroviral regimen 6, 5